Lee Ainslie's Maverick Capital fully exited its position in Centessa Pharmaceuticals (CNTA) during the second quarter of 2026, according to a recent SEC 13F filing. The fund sold its entire stake of 1.85 million shares, which was previously valued at $73.66 million. This disclosure, filed on August 14, 2026, reflects trades made between March 31 and June 30, 2026, and does not represent a real-time transaction.
The sale coincided with the acquisition of Centessa by Eli Lilly and Company, which was announced on March 31, 2026 and completed on June 24, 2026. The acquisition meant that Maverick Capital's shares were tendered as part of the deal. Prior to the sale, the position accounted for approximately 0.85% of Maverick's reported portfolio.